MSLN and neoplasm: Among the most promising approaches are those based on CAR-T cells, in which patient-derived T lymphocytes are engineered to express chimeric antigen receptors recognizing MSLN and, in some cases, to target multiple antigens within the tumor microenvironment (TME) [10, 11].